Aribiolab KRX:261780KOSDAQ
차백신연구소 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days1
DART filings, 7 days3
Articles tracked1since Sep 11
In Q2 2026, Aribiolab reported revenue of ₩0m, down 100.0% year on year, and an operating loss of ₩2.5bn. Aribiolab (차백신연구소) appeared in 1 Korean news article and 3 DART filings over the past seven days. Coverage peaked on Sep 14 with 1 article.
Aribiolab quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩0m | -100.0% | −₩2.5bn | −₩2.7bn |
| Q1 2026 | ₩173m | – | −₩1.7bn | −₩2.1bn |
| Q4 2025 derived | ₩0m | – | −₩5.4bn | −₩5.9bn |
| Q3 2025 | – | – | −₩3.4bn | −₩3.8bn |
| Q2 2025 | ₩159m | – | −₩3.1bn | −₩3.8bn |
| Q1 2025 | – | – | −₩2.4bn | −₩2.6bn |
| Q4 2024 derived | ₩0m | – | −₩2.2bn | −₩4.1bn |
| Q3 2024 | – | – | −₩1.9bn | −₩1.9bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Aribiolab top stories 2 weeks, by number of outlets
- 1